Spruce’s Adrenyx Spinoff Is Taxable, With Just $5 Million Funded
Spruce Biosciences (Nasdaq: SPRB) is planning a taxable spinoff of Adrenyx Biosciences, a new company holding its experimental treatment for classic congenital adrenal hyperplasia. Spruce transferred the program into a wholly owned subsidiary on November 6 and announced the plan November 9, with a distribution of Adrenyx shares to Spruce stockholders targeted for the first half of 2027.… Read More »